C3 Patient Advocate Award 

C3 Rising Star Award

C3 Lifetime Achievement Award 

Eva Korte, MD, PhD

Barry McGrath, PhD

Hywel trained in London at King’s College and St John’s Dermatology Centre where he developed diagnostic criteria for eczema that are now used worldwide. Hywel joined Nottingham University in 1994 where he also worked as a paediatric dermatologist. He founded the Cochrane Skin Group in 1996, the UK Dermatology Clinical Trials Network in 2002, and the Harmonising Outcome Measure for Eczema (HOME) in 2008. He is the second most cited (Scholar) clinical dermatologist globally with 200,000+ citations and 660 publications. Hywel directed the NIHR Health Technology Assessment Programme 2016-2020 and advised the Department of Health on COVID-19 research oversight 2020-2021. He is holder of the Sir Archibald Gray medal, an NIHR senior investigator emeritus and fellow of the Academy of Medical Sciences and received an OBE in 2021 for services to medical research. Hywel was instrumental in the merger between CHORD and CS-COUSIN which led to the creation of C3.

Eva Korte started, together with her team, the development of COS for epidermolysis bullosa (EB) and initiated the COSEB initiative. She developed the COSEB roadmap. They gathered international experts in the field, ensured all stakeholders were involved and are very inclusive for the patient voice with the international patient organization DEBRA.

For the development to COS in EB they divided the disease in 4 subtypes. 

Eva summarized all the existing evidence concerning current outcome used and showed the current heterogeneity in outcomes for EB. She organizes the COSEB meetings online and in person and presented her work with fantastic powerpoint presentations already in many national and international meetings.

She delivers high-quality work, works very independently, has a high level of precision and is a true collaborator. She inspires others who are specialized in bullous diseases of the skin to work on the COS.

She is active in further developing and improving the Chord Cousin Collaboration.

Eva Korte defended her thesis October 20, 2025.

Barry is an inspirational patient advocate in the field of hidradenitis suppurativa (HS). He is President of HS Ireland and a Steering Committee member of HiSTORIC, the HS core outcome set. Dr McGrath holds a science PhD but, in keeping with his humility despite his many achievements, he avoids being referred to as ‘doctor’. He has authored more than 20 publications in the field of HS, including being first author of several papers. Barry is an exemplary colleague, always contributing when asked and being an excellent team player. He is able to represent the whole HS patient community, distilling his extensive experience supporting others with HS into succinct, insightful comments in group discussions. Barry always has important elements to add in consensus work, while never dominating the discussions and encouraging others to contribute. He is an exemplar of best practice in the field of patient advocacy.